Crayon Enters into a Strategic Collaboration Agreement with Amazon Web Services
19.8.2020 07:00:00 EEST | Business Wire | Press release
Crayon, a global leader in digital transformation services, is proud to announce it has entered into a Strategic Collaboration Agreement with Amazon Web Services (AWS). This relationship will help both Crayon and AWS to bring innovation to clients faster, and help them best leverage the transformational power, economics, and agility of the cloud.
Enterprise customers are increasingly relying on AWS to achieve their target business outcomes faster by transitioning to a modern, optimized, cloud-based model. Crayon has a strong track record in migration strategy, implementation, total cost optimization, and cloud economics services. This relationship will help customers have a best-in-class service team to understand what software and infrastructure they have and how to best manage their overall IT estate once they are operating in the cloud.
According to global research and advisory firm Gartner Group, Inc., spending on cloud infrastructure is projected to grow by nearly 60% in the next two years, while investments in data center systems is projected to decline. This means organizations will have to be smart about their IT investments. Crayon can provide the guidance, tools and expertise to properly manage costs, governance and security in the cloud.
“Collaborating with AWS has been a part of our strategy to build an even stronger commitment to our customers’ success. Alongside AWS we will deliver services to enable our customers to digitally transform, achieve operational efficiencies, and maximize cost optimization to strengthen their performance,” says Crayon CEO Torgrim Takle. “Putting the customer first is in the DNA of Crayon and AWS, and together we will serve more organizations worldwide with world-class solutions.”
Crayon has spent the last several years developing and diversifying its cloud services offerings. Both Crayon and AWS expect this latest collaboration to benefit customers wanting to optimize their overall IT estate utilizing best practices in their cloud adoption framework.
One of those customers who has seen first-hand the power of Crayon and AWS working together is The Future Group, a global company that handles many high-profile projects including those from The Weather Channel and the Super Bowl.
"At The Future Group we have had the great fortune to be able to draw on Crayon's deep knowledge in software development, cloud operations and AWS's wide range of services, to help us build and deliver one of the world's most advanced Mixed Reality solutions for the broadcast industry in record time," said Marcus Brodersen, CEO in The Future Group.
Crayon serves customers in more than 45 countries spanning Europe, the Middle East, Africa, North America, and the Asia-Pacific region.
“Crayon has demonstrated a longstanding commitment of putting customers first and helping them find effective ways to optimize the costs of their IT spend,” said Doug Yeum, Head of Worldwide Channel and Alliances, Amazon Web Services, Inc. “We are delighted to collaborate with Crayon to continue guiding customers through their cloud adoption journey.”
About Crayon:
Crayon helps customers build the commercial and technical foundation for a successful digital transformation journey through a reliable services framework allowing our customers to right-size and optimize their IT estates to unlock technology’s potential and innovation. Headquartered in Oslo, Norway, Crayon has over 1600 employees across approximately 50 locations worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005014/en/
Contact information
Melanie Coffee
PR and Media Relations Director
Melanie.coffee@crayon.com
+47 46 74 8648
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom